4,714 Shares in Merck & Co., Inc. (MRK) Purchased by Apollon Wealth Management LLC

Apollon Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,714 shares of the company’s stock, valued at approximately $351,000.

A number of other institutional investors also recently bought and sold shares of MRK. Contravisory Investment Management Inc. increased its position in Merck & Co., Inc. by 186.4% during the 4th quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock worth $50,000 after purchasing an additional 425 shares in the last quarter. Arlington Partners LLC increased its position in Merck & Co., Inc. by 93.5% during the 4th quarter. Arlington Partners LLC now owns 828 shares of the company’s stock worth $63,000 after purchasing an additional 400 shares in the last quarter. Advisors Preferred LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter worth about $66,000. Financial Gravity Companies Inc. purchased a new stake in Merck & Co., Inc. during the 4th quarter worth about $66,000. Finally, Mark Sheptoff Financial Planning LLC increased its position in Merck & Co., Inc. by 150.0% during the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the company’s stock worth $76,000 after purchasing an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 73.85% of the company’s stock.

A number of analysts recently commented on MRK shares. BMO Capital Markets cut Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective for the company. in a research report on Wednesday, January 23rd. Zacks Investment Research cut Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 24th. Argus lifted their price objective on Merck & Co., Inc. to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 20th. Cantor Fitzgerald started coverage on Merck & Co., Inc. in a report on Friday, February 22nd. They issued an “overweight” rating and a $95.00 price target for the company. Finally, ValuEngine cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $82.92.



In other news, EVP Robert M. Davis sold 192,572 shares of Merck & Co., Inc. stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $82.38, for a total value of $15,864,081.36. Following the transaction, the executive vice president now directly owns 330,232 shares of the company’s stock, valued at approximately $27,204,512.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Merck & Co., Inc. acquired 4,121,683 shares of Merck & Co., Inc. stock in a transaction dated Monday, April 8th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $65,946,928.00. The disclosure for this purchase can be found here. Insiders sold a total of 766,625 shares of company stock valued at $62,212,275 in the last 90 days. 0.27% of the stock is owned by company insiders.

MRK opened at $77.55 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.37 and a quick ratio of 1.06. The stock has a market capitalization of $207.80 billion, a price-to-earnings ratio of 17.87, a price-to-earnings-growth ratio of 1.83 and a beta of 0.58. Merck & Co., Inc. has a 12 month low of $57.49 and a 12 month high of $83.85.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.05 by $0.17. The company had revenue of $10.82 billion during the quarter, compared to analysts’ expectations of $10.45 billion. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.05 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 4.72 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “4,714 Shares in Merck & Co., Inc. (MRK) Purchased by Apollon Wealth Management LLC” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://dakotafinancialnews.com/2019/05/16/4714-shares-in-merck-co-inc-mrk-purchased-by-apollon-wealth-management-llc.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: Why do companies issue convertible shares?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.